2023-10-13 22:26:40
The American laboratory Pfizer announced on Friday that it is reducing its forecasts for the full financial year 2023, due to lower than expected sales of products (vaccine and drugs) related to Covid-19, according to AFP.
Paxlovid – Pfizer’s antiviral once morest COVIDPhoto: Dreamstime.com
Its sales would be between $58 billion and $61 billion, compared with $67 billion and $70 billion previously forecast, and net profit per share – the market’s benchmark – between $1.45 and $1.65 (3.25 and $3.45 previously).
The company said it took a $5.5 billion inventory write-down in the third quarter.
Paxlovid, an antiviral drug to treat COVID-19 developed by Pfizer, will arrive in Romania in the next period. Previously, only the antiviral Molnupiravir, developed by Merck, was available in Romania to treat COVID-19. (photo: Dreamstime.com)
1697263799
#Pfizer #sales #expectations #antiCovid #treatments
